

RESEARCH ARTICLE

 OPEN ACCESS  Check for updates

Curcumin inhibits growth of *Porphyromonas gingivalis* by arrest of bacterial dipeptidyl peptidase activity

Hiroki Murai^{a,b}, Masae Kuboniwa^{a,c}, Miho Kakiuchi^a, Reiko Matsumura^{a,b}, Yoshihiko Hirata^{a,b} and Atsuo Amano^{a,c}

^aJoint Research Laboratory for Advanced Oral Environmental Science (SARAYA), Osaka University Graduate School of Dentistry, Osaka, Suita, Japan; ^bSaraya Research Institute, Saraya Co., Ltd, Osaka, Kashiwara, Japan; ^cDepartment of Preventive Dentistry, Osaka University Graduate School of Dentistry, Osaka, Suita, Japan

ABSTRACT

Background: Curcumin is a multi-functional polyphenol with anti-bacterial and anti-inflammatory effects and may have potential for treatment of periodontal diseases. The present study was conducted to examine the molecular basis of the anti-bacterial effect of curcumin against *Porphyromonas gingivalis* using metabolome analysis.

Materials and Methods: *P. gingivalis* were incubated with 10 µg/mL curcumin, and then metabolites were analyzed with CE-TOF/MS. Expression levels of sigma factors were also evaluated using RT-PCR assays. The activities of dipeptidyl peptidases (DPPs) were assessed by examining the degradation reactions of MCA-labeled peptides.

Results: The relative amounts of various glycolytic amino acids were significantly decreased when *P. gingivalis* was incubated with curcumin. Furthermore, the metabolites on the amino acid degradation pathway, including high-energy compounds such as ATP, various intermediate metabolites of RNA/DNA synthesis, nucleoside sugars and amino sugars were also decreased. Additionally, the expression levels of sigma-54 and sigma-70 were significantly decreased, and the same results as noted following nutrient starvation. Curcumin also significantly suppressed the activities of some DPPs, while the human DPP-4 inhibitors markedly inhibited the growth of *P. gingivalis* and activities of the DPPs.

Conclusions: Curcumin suppresses the growth of *P. gingivalis* by inhibiting DPPs and also interferes with nucleic acid synthesis and central metabolic pathways, beginning with amino acid metabolism.

ARTICLE HISTORY

Received 3 October 2023

Revised 19 June 2024

Accepted 23 June 2024

KEYWORDS

Anti-bacterial agent; polyphenol; curcumin; *porphyromonas gingivalis*; metabolome analysis; dipeptidyl peptidase



Introduction


Periodontal disease is a major chronic infectious disorder found in humans [1] and known to have an influence on oral as well as systemic health [2]. The condition is initiated by dysbiosis caused by an imbalance with host defense systems in subgingival biofilm. *Porphyromonas gingivalis* is considered to be a keystone pathogen and known to play a central role in initiation of dysbiosis [3], and various functional materials for prevention of periodontal disease have been examined [4].

Curcumin, a major constituent of turmeric rhizomes (*Curcuma longa*) [5], has been reported to have a variety of functions, including anti-oxidant [6,7], anti-inflammatory [7–9], anti-tumor [10,11] and anti-bacterial [12,13] effects. Thus, curcumin may have potential for treatment of periodontal diseases. We previously showed that curcumin markedly inhibited the growth of *P. gingivalis*, and prevented biofilm formation as well as bacterial protease activity

at a low concentration [14]. It has also been reported that curcumin clearly limited the expression of inflammatory cytokines (IL-6, IL-1 β , TNF- α) and inhibited invasion of human gingival epithelial cells by outer membrane vesicles of *P. gingivalis* [15]. Furthermore, clinical trials of curcumin used in combination with various materials such as gels, collagen sponges and mouthwash have found clear effects on clinical manifestations of periodontal disease [16–18].

Nevertheless, the mechanism of the antimicrobial action of curcumin is unclear. A previous report presented findings suggesting that curcumin caused damage to the bacterial membrane of *Staphylococcus aureus* [19], while another study found that curcumin disturbed *Bacillus subtilis* cell division by inhibiting the activity of GTPase [20]. On the other hand, some reports have suggested that only negligible bactericidal effects against some oral bacterial species such as *Aggregatibacter actinomycetemcomitans* [14] and *Streptococcus mitis* [21]. Thus, while curcumin seems to exhibit species-specific

CONTACT Hiroki Murai  murai-h@saraya.com  Joint Research Laboratory for Advanced Oral Environmental Science (SARAYA), Osaka University Graduate School of Dentistry, 1-8 Yamadaoka, Suita, Osaka 565-0871, Japan

 Supplemental data for this article can be accessed online at <https://doi.org/10.1080/20002297.2024.2373040>

© 2024 Saraya Co., Ltd. Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

antimicrobial activities, the molecular basis remains to be elucidated.

The present study was conducted to investigate the mechanism of the antimicrobial action of curcumin toward *P. gingivalis*.

Materials and methods

Bacterial strains & culture conditions

Porphyromonas gingivalis ATCC33277 and *Streptococcus oralis* ATCC6249 were obtained from ATCC (Manassas, USA). KDP136 (*P. gingivalis* ATCC 33,277 *rgpA:erm rgpB:tetQ kgp:cat*) was kindly provided by Prof. Koji Nakayama (Department of Microbiology and Oral Infection, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan). *P. gingivalis* was anaerobically cultured (80% N₂, 10% CO₂, 10% H₂) at 37°C in 30 g/L trypticase soy broth (TSB; Becton, Dickinson and Company, Franklin Lakes, NJ, USA) containing 5 mg/L hemin (Sigma-Aldrich, St Louis, MO, USA) and 1 mg/L menadione (Fujifilm Wako Pure Chemical Corporation, Osaka, Japan), while *S. oralis* was aerobically cultured at 37°C in Todd Hewitt broth (THB; Becton, Dickinson and Company).

Growth assays

P. gingivalis and *S. oralis* were separately incubated in the presence of curcumin (Fujifilm Wako Pure Chemical Corporation) serially diluted two-fold from 500 to 7.8 µg/mL, or sitagliptin monophosphate (Sigma-Aldrich) or Val-boroPro (Selleck Chemicals, TX, USA) serially diluted two-fold from 10,000 to 625 µg/mL. Those were dissolved with 0.1% dimethyl sulfoxide (DMSO) to OD_{600 nm} ≈ 0.05 and dispensed in 96-well plates at 200 µL/well. Following incubation, the lowest concentration at which no growth (OD_{600 nm} < 0.1) was observed was defined as the minimum inhibitory concentration (MIC).

Intracellular metabolite extraction

The concentration of curcumin was based on a previous report [14]. *P. gingivalis* cells were cultured anaerobically in a liquid medium containing 0 or 10 µg/mL curcumin dissolved with 0.1% DMSO adjusted to OD_{600 nm} ≈ 0.1 at 37°C for 24 h. The bacterial cells were then collected and suspended in methanol as previously described [22].

CE-TOF/MS measurement conditions

The untargeted metabolome analysis with CE-TOF/MS was performed using an Agilent CE-TOFMS system (Agilent Technologies, Santa Clara, CA) equipped with a fused silica capillary [50 µm (inner diameter) × 80 cm]. For measurements of cationic/anionic

metabolites, running buffer, a solution composed of Cation Buffer Solution [H3301–1001; Human Metabolome Technologies (HMT), Tsuruoka, Japan], and Anion buffer solution (H3302–1021) were used, with CE voltage + 27 kV/+ 30 kV, MS ionization ESI positive/negative, MS capillary voltage 4000 V/3500 V, MS scan range 50–1000 m/z and HMT Sheath Liquid (H3301–1020). Identification of metabolites and measurement of relative amounts were performed using MASTER HANDS (version 2.1.0.1, 2.9.0.9; Keio University, Tokyo, Japan) and the HMT metabolite database based on internal standards (HMT).

Determination of gene expression

For the low nutrient condition, the liquid medium was diluted 100-fold with PBS, and then *P. gingivalis* cells were suspended in low nutrient medium adjusted to OD_{600 nm} ≈ 0.5 and anaerobically incubated at 37°C for 3 h. Next, the cells were suspended in curcumin medium adjusted to OD_{600 nm} ≈ 0.05 and incubated for 9 h, then collected by centrifugation (7500 rpm, 7 min, 4°C). Total RNA was extracted using TRIzol Reagent® (Thermo Fisher Scientific Inc., MA, USA) and an RNeasy kit (QIAGEN N.V., Hilden, Germany) according to the manufacturer's recommendations, then reverse transcribed to cDNA using iScript master mix (Bio-Rad Laboratories, Inc., CA, USA). Real-time PCR was performed using a KAPA SYBR Fast qPCR kit (NIPPON Genetics Co., Ltd., Tokyo, Japan). Primer sets are shown in Table 1. Gene expression levels were compared using a comparative Ct method. Acquired data were normalized to the expression level of the 16s rRNA gene.

Dipeptidyl peptidase activity

Measurements to determine dipeptidyl peptidase (DPP) activity were performed as previously described [25]. Briefly, *P. gingivalis* KDP136 cells were washed with PBS followed by centrifugation (7500 rpm, 7 min, 4°C), then suspended to OD_{600 nm} ≈ 0.05 in 50 mM phosphate buffer containing 5 mM EDTA, 100 mM NaCl with or without 10 µg/mL curcumin, 5000 µg/mL sitagliptin monophosphate and 2500 µg/mL Val-boroPro dissolved with 0.1%

Table 1. Primers.

Name		Sequence (5'–3')	Reference
PGN_0638	Fw	CGGATTGATCAAAGCGGCAG	This study
(<i>rpoD</i>)	Rv	TTCCACCTGATTCAGTGGC	
PGN_1202	Fw	GCCGAAGCAACCATGAACAG	This study
(<i>rpoN</i>)	Rv	CTGATAGACCGACTGACGC	
PGN_0180	Fw	CTGTGTGTTTATGGCAAACCTC	Amano et al. [23]
(<i>fimA</i>)	Rv	AACCCCGCTCCCTGTATCCGA	
16SrRNA	Fw	TGTAGATGACTGATGGTAAAACC	McClellan et al. [24]
	Rv	ACGTCATCCCCACCTTCTC	

DMSO. Following suspension, the cells were anaerobically incubated at 37°C for 3 h, then methylcoumarin amide (MCA)-labeled peptides (Gly-Pro-MCA, Lys-Ala-MCA, Met-Leu-MCA, Leu-Asp-MCA: PEPTIDE INSTITUTE, Inc, Osaka, Japan) were added at a final concentration 20 μ M, and incubation was performed at 37°C for 3 h. Fluorescence intensity (λ_{ex} = 380 nm, λ_{em} = 460 nm, 1.0 s) was determined using a plate reader ARVO MX (PerkinElmer, Inc), then calculated as free aminomethylcoumarin (AMC) concentration using a calibration curve prepared by use of a reagent (PEPTIDE INSTITUTE, Inc.).

Statistical analysis

All obtained data were examined three times using a statistical process. The results, except for those obtained with metabolic analysis, were evaluated with a t-test and Dunnett's test using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan). Multiple comparisons of metabolomic data were performed with Welch's t-test. Principal component analysis (PCA) was performed using SIMCA, ver. 17 (Sartorius, Göttingen, Germany).

Results

Effects of curcumin on *P. gingivalis* metabolomic profiles

First, an untargeted metabolome analysis was performed to examine curcumin-treated *P. gingivalis*. PC1 and PC2 scores were plotted using principal component analysis (PCA) and are shown in Figure 1(a). The curcumin-treated and control groups were separated by the PC1 component. Figure 1(b) shows a plot of factor loadings for each metabolite. In

the PC1 component, several amino acids (ornithine, proline, serine, alanine, glutamic acid, glycine, lysine, arginine, citrulline, tryptophan, phenylalanine), NAD and tripeptide (Ile-Pro-Pro) showed characteristic fluctuations. Relative peak areas of amino acids are presented in Figure 2. Proline, ornithine, valine, alanine, serine, lysine, glycine, glutamic acid, threonine and aspartic acid were significantly decreased in *P. gingivalis* treated with curcumin, whereas phenylalanine and tryptophan were significantly increased. Although the differences were not statistically significant, asparagine, glutamine and β -alanine showed a decreasing trend, and arginine and citrulline an increasing trend. Therefore, we focused on fluctuation of metabolites on the metabolic pathway starting from glycogenic amino acids, with reference to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database (<https://www.genome.jp/kegg/pathway.html>). Figure 3 shows metabolite fluctuations on the glycogenesis and pentose phosphate pathways, as well as the nucleoside-sugar and sugar-amino acid metabolic pathways. When *P. gingivalis* was treated with curcumin, most of the detected metabolites on these pathways were significantly decreased or showed a decreasing trend. Fluctuations of metabolites on the purine and pyrimidine metabolic pathways, which represent nucleic acid materials and energy currency, are demonstrated in Figure 4. In addition, curcumin was found to cause a significant decrease in most of the metabolites of the purine and pyrimidine metabolic pathways in *P. gingivalis*.

Expression of sigma factors

Findings indicating decreased glycogenic amino acids and downstream metabolites suggested that the bacterial response to nutrient starvation is activated by curcumin. Therefore, the mRNA expression




Figure 1. Principal component analysis of metabolites detected in *P. gingivalis*. (a) PC1 and PC2 score plots of results of principal component analysis for the control (green: Control 1 ~ 3) and curcumin-treated (blue: C1 ~ 3) groups. (b) Factor loading for each metabolite contributing to PC1 and PC2.




Figure 2. Effects of curcumin on amino acids in *P. gingivalis*. Corrected peak areas of amino acids detected in *P. gingivalis* cultured for 24 hours in liquid medium (white) and in TSB with 10 µg/mL curcumin (shaded). Cys was below the detection limit in all samples and excluded.

Note: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ND: below detection limit ($n = 3$)

level of the RNA polymerase sigma subunit, which indicates a response to nutrient starvation stress in eubacteria, was examined. Identified in *P. gingivalis* were a gene encoding sigma-54, termed *rpoN* (PGN_1202), and a gene encoding sigma-70, termed *rpoD* (PGN_0638), which are considered to be related to nutrient starvation [25], though their expression levels have not been reported. In the present study, a low nutrient medium diluted with PBS was used, and the expression levels of PGN_0638 and PGN_1202 were determined. As shown in Figure 5 (a), the expression levels of both were significantly decreased in that low nutrient condition. The expression levels of those genes following stimulation with curcumin were also examined, which revealed a significant decrease in each, the same as noted in the low nutrient condition (Figure 5(b)).

Dipeptidyl peptidase activities in *P. gingivalis* treated with curcumin

The activities of some DPPs (DPP4, DPP5, DPP7, DPP11) in *P. gingivalis*, determined by measuring the fluorescence intensity of AMC derived from a decomposition product of MCA-labeled synthetic substrates, were previously reported [27]. In the present study, DPPs in *P. gingivalis* treated with curcumin were examined. In order to avoid the effects of gingipain, a deletion mutant with knocked out genes coding gingipain of *P. gingivalis* (KDP136) was used. Following incubation with curcumin, substrates were added, and fluorescence intensity was determined. As shown in Figure 6, decomposition of Gry-Pro-MCA (substrate of DPP4), Lys-Ala-MCA (substrate of DPP5), Met-Leu-MCA (substrate DPP7) and Leu-Asp-MCA (substrate of DPP11) was inhibited by curcumin.

DPP-4 inhibitors have inhibitory effect on bacterial growth

Next, whether inhibition of DPP would lead to arrest of *P. gingivalis* growth was examined. Results showing the MICs of human DPP-4 inhibitors (Sitagliptin monophosphate, Val-boroPro) and curcumin against *P. gingivalis* and *S. oralis* are presented in Table 2. Both Sitagliptin monophosphate and Val-boroPro markedly inhibited the growth of *P. gingivalis* at concentrations of 5000 and 2500 µg/mL, whereas those DPP-4 inhibitors had negligible effects on *S. oralis*. In addition, GryPro-MCA, Lys-Ala-MCA and Met-Leu-MCA degradation were inhibited by the DPP-4 inhibitors at the MIC noted for *P. gingivalis* (Figure 7).

Discussion

The metabolomic profile of *P. gingivalis* was examined to elucidate the molecular basis of the anti-bacterial effects of curcumin, and the results showed that the metabolism of various amino acids was altered. *P. gingivalis* is an asaccharolytic bacterium that does not assimilate sugars, such as glucose, lactose, galactose and cellobiose [28], while the pathogen assimilates amino acids obtained from degraded proteins as a carbon source [29]. In particular, glutamic acid and aspartic acid are the starting materials for the energy acquisition pathway, and energy sources are acquired through a metabolic process to synthesize short-chain fatty acids such as acetic acid, propionic acid and butyric acid [30]. It has also been reported that metabolites of the glycolytic pathway are synthesized by glycine, serine, alanine, glutamic acid and aspartic acid as starting materials, after which nucleic acid and polysaccharide are




Figure 3. Effects of curcumin on metabolites in (a) glycolytic pathway and TCA cycle, (b) pentose phosphate pathway and (c) amino sugars and nucleotide sugars in *P. gingivalis*. Corrected peak areas of amino acids detected in *P. gingivalis* incubated for 24 hours in liquid medium (white) and in liquid medium with 10 µg/mL curcumin (shaded) are shown.

Note: * $p < 0.05$, ** $p < 0.01$, ND: below detection limit ($n = 3$)




Figure 4. Effects of curcumin on metabolites in (a) purine metabolic pathway and (b) pyrimidine metabolic pathway in *P. gingivalis*. Corrected peak areas of amino acids detected in *P. gingivalis* incubated for 24 hours in liquid medium (white) and in liquid medium with 10 µg/mL curcumin (shaded) are shown.

Note: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ND: below detection limit ($n = 3$)




Figure 5. Effects of curcumin on mRNA expression level of sigma factor in *P. gingivalis*. (a) mRNA expression levels of PGN_0638 (*rpoD*) and PGN_1202 (*rpoN*) genes in *P. gingivalis* cultured for three hours in liquid medium (white) or 1/100 diluted liquid medium with PBS (dotted). (b) mRNA expression levels of PGN_0638 and PGN_1202 genes in *P. gingivalis* cultured for 15 hours in liquid medium (white) or in liquid medium with 10 µg/mL curcumin (shaded). Result of the PGN_0180 (*fimA*) gene with unchanged expression are presented as a control [26]. Expression levels are shown relative to 16sRNA gene.

Note: * $p < 0.05$, ** $p < 0.01$ ($n = 3$)




Figure 6. Inhibitory effects of curcumin on activities of DPPs in *P. gingivalis*. (a) Gly-Pro-MCA (substrate of DPP4), (b) Lys-Ala-MCA (substrate of DPP5), (c) Met-LeuMCA (substrate of DPP7) and (d) Leu-Asp-MCA (substrate of DPP11) were added to *P. gingivalis* KDP136 suspensions in reaction buffer without curcumin (white circles) and with 10 µg/mL of curcumin (black circles). Degradation activity was determined based on fluorescence intensity of AMC and converted to concentration by using a calibration curve of the standard product.

Note: *** $p < 0.001$ ($n = 3$)

Table 2. Growth inhibitory effects of DPP-4 inhibitor and curcumin on *P. gingivalis* and *S. oralis*.

	MIC (µg/mL)	
	<i>P. gingivalis</i>	<i>S. oralis</i>
Sitagliptin monophosphate	5000	10000
Val-boroPro	2500	10000
Curcumin	10	125




Figure 7. Inhibitory effects of DPP-4 inhibitors on activities of DPPs against *P. gingivalis*. (a) Gly-Pro-MCA, (b) Lys-Ala-MCA, (c) Met-LeuMCA and (d) Leu-Asp-MCA (substrate of DPP11) were added to *P. gingivalis* KDP136 suspensions in reaction buffer without a DPP-4 inhibitor (white circles), with 5000 µg/mL sitagliptin phosphate (squares), or with 2500 µg/mL Val-boroPro (diamond shapes). Degradation activity was determined based on fluorescence intensity of AMC and converted to concentration using a calibration curve of the standard product.

Note: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ ($n = 3$)

synthesized through the pentose phosphate pathway, and nucleoside sugar and sugar amino acid metabolism [31]. Therefore, a decrease in the supply of

amino acids has effects on the growth of *P. gingivalis*. In the present study, metabolites involved in glyco-genesis, the pentose phosphate pathway and the nucleoside-sugar and sugar-amino acid metabolism pathways that start from amino acids were found to be decreased in curcumin-treated *P. gingivalis* (Figure 8), while purine and pyrimidine metabolic pathway metabolites synthesized from those metabo-lites were also decreased. These results suggest that curcumin inhibits bacterial growth by reducing the supply of glyco-genic amino acids, which are

a nutrient source, thereby preventing synthesis of var-ious downstream metabolites.

Various bacterial amino acids have been found to be decreased in quantity by curcumin, whereas sev-eral amino acids are increased. As for tryptophan, *P. gingivalis* possesses a gene (PGN_0880) encoding a tryptophanase (EC: 4.1.99.1) that synthesizes indole from tryptophan. Also, enzyme activities have been reported to be controlled by the concentration of pyridoxal-5-phosphate as a cofactor [32]. A decrease in pyridoxal-5'-phosphate by curcumin was noted in




Figure 8.Metabolic profile of central metabolism in *P. gingivalis* treated with curcumin. Fluctuations of mean values of metabolites as compared to the control are visualized (green horizontal arrows: 0.8 < relative value < 1.2, light blue lower arrows: 0.5 < relative value ≤ 0.8, blue lower arrows: relative value ≤ 0.5). Metabolic enzymes are indicated by arrows and EC numbers are shown between each metabolite.

the present results. Since the biosynthetic pathway of pyridoxal-5'-phosphate in *P. gingivalis* is assumed to be via the pentose phosphate pathway [33], tryptophan likely accumulates by reducing the activity of tryptophanase, which is induced by decreases in pyridoxal-5'-phosphate and metabolites of the pentose phosphate pathway caused by curcumin (Figure S1). Metabolomic pathways starting from phenylalanine have not been reported for *P. gingivalis*. The pathogen expresses a Lys E family transporter that discharges metal ions and neutral amino acids (PGN_0861) [34]; thus, it is possible that curcumin inhibits the amino acid transporter, while some amino acids that can be utilized as secondary metabolites become accumulated in *P. gingivalis*. As for arginine, it is thought to be a factor in polyamine metabolism, as *P. gingivalis* has a number of enzymes that synthesize polyamines from arginine. Findings in the present study related to the polyamine metabolic pathway showed that agmatine and putrescine, located downstream of arginine, were increased by curcumin, while N-acetylputrescine was decreased (Figure S2). Diamine N-acetyltransferase (EC: 2.3.1.57) catalyzes the reaction from putrescine and acetyl-CoA to N-acetylputrescine. However, as shown in Figure 8, curcumin-induced reduction of acetyl-CoA resulted in suppression of N-acetylputrescine synthesis and accumulation of putrescine. Furthermore, it has been reported that plant and bacterial agmatine deiminase (EC: 3.5.3.12) and arginine decarboxylase (EC 4.1.1.19) are inhibited by putrescine and agmatine [35–37]. Therefore, arginine and agmatine in *P. gingivalis* treated with curcumin become accumulated by feedback inhibition. Recently, polyamines have been reported to be associated with bacterial stress response and pathogenicity [38]. Also, putrescine produced by *Fusobacterium nucleatum* was shown to enhance biofilm formation by *P. gingivalis* [39]. On the other hand, *P. gingivalis* biofilm formation was reported to be inhibited by curcumin [14]. This contradiction may be because of suppression of adhesion factors in *P. gingivalis* by curcumin [40]. It will be necessary to further examine the effects of polyamine metabolism fluctuation caused by curcumin on stress responses and infectivity.

Results of the present metabolomic analysis indicate that curcumin inhibits the growth of *P. gingivalis* by nutrient starvation, induced by inhibition of amino acid uptake. Eubacteria respond to various stresses by regulating the expression of the sigma factor, a subunit of RNA polymerase [25]. In *E. coli*, the expression of 'sigma-38' was shown to be increased under nutrient starvation and in response to starvation stress by competing with 'sigma-70' [41]. Although *P. gingivalis* has a sigma-70 gene (*rpoD* : PGN_0638), it does not possess a gene homologous to sigma-38. Therefore, it is suggested that

another sigma factor has a role in starvation stress response. *P. gingivalis* possesses a sigma-54 gene (*rpoN* : PGN_1202), and *rpoN* has been shown to have a relationship to regulation of amino acids, as nitrogen sources, in *Escherichia coli* as well as other bacteria [25]. Therefore, the mRNA expressions of PGN_0638 and PGN_1202 in *P. gingivalis* cultured under a low nutrient condition and with curcumin treatment were examined in the present study. Those results showed that the expression level of each was decreased by starvation stress and treatment of curcumin, suggesting that curcumin-treated *P. gingivalis* may have a condition similar to a low nutrient state in regard to expression level. In contrast to findings of other bacteria previously reported, the expression levels of both sigma-54 and sigma-70 in *P. gingivalis* were decreased by nutrient starvation. However, PGN_1202 in *P. gingivalis* is an essential gene, different from other bacteria [42], while another report noted that the amount of sigma-54 in *Pseudomonas putida* was not changed under a nitrogen starvation stress condition [43]. Although the functions of sigma factors remain largely unknown, results of those previous studies as well as the present suggest that *P. gingivalis* sigma factors have unique functions.

The present findings indicate that curcumin has effects on enzymatic activities involved in amino acid uptake by *P. gingivalis*. The pathogen degrades proteins (polypeptides) by gingipain, a protease localized on the outer membrane, and generated oligopeptides are degraded to dipeptides by DPPs, which are localized in periplasm, then dipeptides are degraded to amino acids or directly used for various metabolic activities [44]. We previously reported that curcumin inhibits the activity of gingipain [14], though it is thought that curcumin has effects on other target enzymes, because growth of the KDP136 strain was also inhibited by curcumin in the present study (Figure S3). Therefore, degradation of oligopeptides by DPPs received focus in the present experiments. A previous study found that the activities of some DPPs in *P. gingivalis* could be measured by the use of MCA-labeled peptides [27], thus DPPs treated with curcumin were examined, which showed inhibition of the activities of DPP4, DPP5, DPP7 and DPP11. A recent report noted that the DPPs examined in the present study are able to recognize amino acids in oligopeptides such as proline (DPP4), hydrophobic amino acids and alanine (DPP5), hydrophobic amino acid (DPP7) and aspartic acid or glutamic acid (DPP11) [44]. Analysis of the metabolomic profile of *P. gingivalis* after treatment with curcumin showed that all of those amino acids were reduced. In addition, another study reported that curcumin binds to the active site of human DPP-4 and was found to directly inhibit enzyme activity in *in silico*

and *in vitro* experiments [45]. Since curcumin is a relatively small molecule (molecular weight: 368.4), it is capable of penetration into the periplasm, thus suggesting an ability to inhibit the enzymatic activity of DPPs.

To confirm that inhibition of DPP activities leads to growth inhibition of *P. gingivalis*, the effects of DPP inhibitors were assessed in the present investigation. A previous study reported findings obtained with some human DPP-4 inhibitors [46]. Sitagliptin monophosphate is considered to be a typical inhibitor and used for diabetes treatment [47], while Val-boroPro has been reported to have inhibitory activities against human DPP-8, DPP-9 and PEP, as well as human DPP-4, and considered to show a broad spectrum of effects [48]. *P. gingivalis* DPP4 has a structure similar to that of human DPP-4, though it has an approximately 32% amino acid sequence homology, and inhibitory activity with use of inhibitors has also been reported [49]. As a result, the growth inhibition effects of a DPP-4 inhibitor against *P. gingivalis* and *S. oralis*, oral indigenous bacteria, were examined. The results showed that sitagliptin monophosphate and Val-boroPro at 5000 and 2500 µg/mL inhibited the growth of *P. gingivalis*, and both inhibited the growth of *S. oralis* at 10,000 µg/mL. As for curcumin, *P. gingivalis* growth was inhibited at 10 µg/mL, while that of *S. oralis* was inhibited at 125 µg/mL. Therefore, the DPP-4 inhibitors and curcumin showed similar effects on growth inhibition. Furthermore, we examined the effects of DPP-4 inhibitors on the activity of DPPs. The results showed that sitagliptin phosphate significantly reduced the activity of DPP4, DPP5 and DPP7, while Val-boroPro also reduced the activity of DPP4, DPP5, DPP7 and DPP11. These results indicate that these DPP-4 inhibitors suppress the growth of *P. gingivalis* by inhibiting the activity of DPPs, especially DPP4, DPP5 and DPP7.

Results obtained in this study suggest a novel anti-bacterial mechanism of curcumin. It was previously reported that curcumin reduces the uptake of dipeptides and amino acids possessed by *P. gingivalis* by inhibiting the activity of gingipain [14], while the present findings showed that they also inhibit the activities of DPPs. Decreases in those induce the fluctuation of metabolites, such as the glycosylation pathway, energy acquisition pathway, pentose phosphate pathway, nucleoside sugars, glyco-amino acids, purine metabolism and pyrimidine metabolisms. Therefore, a decrease in metabolites necessary for proliferation may lead to growth suppression. On the other hand, bacteria such as *Streptococcus* possess metabolic pathways that start from sugars and do not depend on proteins for energy acquisition [50], thus curcumin is thought to have little effect on growth inhibition.

Nevertheless, it is difficult to compare the anti-bacterial effects of curcumin, because the solubilization and purification conditions have been found to differ [51,52]. Accordingly, a future investigation of the selective anti-bacterial effects of curcumin on a variety of bacteria using unified test systems will be necessary for accurate comparisons.

Turmeric, which contains a large amount of curcumin, is used as a spice and has abundant dietary applications, thus is considered to be safe and functional for treatment in the oral cavity. It is expected that details regarding the anti-bacterial effects of curcumin revealed by the present study will contribute to development of oral care agents for prevention of periodontal disease.

Conclusions

Curcumin inhibits *P. gingivalis* DPPs activity and also interferes with nucleic acid synthesis and central metabolic pathways, beginning with amino acid metabolism, with those fluctuations inducing starvation and growth inhibition. Although additional studies are necessary, the present results provide important details regarding the anti-bacterial mechanism of curcumin.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was performed by the Joint Research Laboratory for Advanced Oral Environmental Science (SARAYA), established by Osaka University Graduate School of Dentistry and SARAYA Co., Ltd.

Authors' contributions statement

H.M., M.Ku. and A.A. designed the study, main conceptual ideas, and proof outline. M.Ku., M.Ka., and H.M. collected the data. H.M., M.Ku., and A.A. analyzed the data. M.Ka., R.M., and Y.H. aided in interpreting the results. A. A. supervised the project. H.M. wrote the manuscript, with support from M.Ku. and A.A. All authors discussed the results and commented on the manuscript.

References

- [1] Genco RJ, Borgnakke WS. Risk factors for periodontal disease. *Periodontol* 2000. 2013;62(1):59–94. doi: 10.1111/j.1600-0757.2012.00457.x
- [2] Bui FQ, Almeida-da-Silva CLC, Huynh B, et al. Association between periodontal pathogens and systemic disease. *Biomed J*. 2019;42(1):27–35. doi: 10.1016/j.bj.2018.12.001
- [3] Hajishengallis G, Lamont RJ. Dancing with the stars: how choreographed bacterial interactions dictate nosymbiosis and give rise to keystone pathogens,

- accessory pathogens, and Pathobionts. *Trends Microbiol.* 2016;24(6):477–489. doi: [10.1016/j.tim.2016.02.010](https://doi.org/10.1016/j.tim.2016.02.010)
- [4] de Sousa Et, de Araújo Jsm, Pires AC, et al. Local delivery natural products to treat periodontitis: a systematic review and meta-analysis. *Clin Oral Investig.* 2021;25(7):4599–4619. doi: [10.1007/s00784-021-03774-2](https://doi.org/10.1007/s00784-021-03774-2)
- [5] Fuloria S, Mehta J, Chandel A, et al. A comprehensive review on the therapeutic potential of curcuma longa Linn. In relation to its major active constituent curcumin. *Front Pharmacol.* 2022;13:820806. doi: [10.3389/fphar.2022.820806](https://doi.org/10.3389/fphar.2022.820806)
- [6] Motterlini R, Foresti R, Bassi R, et al. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. *Free Radic Biol Med.* 2000;28(8):1303–1312. doi: [10.1016/s0891-5849\(00\)00294-x](https://doi.org/10.1016/s0891-5849(00)00294-x)
- [7] Dehzad MJ, Ghalandari H, Nouri M, et al. Antioxidant and anti-inflammatory effects of curcumin/turmeric supplementation in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. *Cytokine.* 2023;164:156144. doi: [10.1016/j.cyto.2023.156144](https://doi.org/10.1016/j.cyto.2023.156144)
- [8] Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (curcuma longa). *J Altern Complement Med.* 2003;9(1):161–168. doi: [10.1089/107555303321223035](https://doi.org/10.1089/107555303321223035)
- [9] Peng Y, Ao M, Dong B, et al. Anti-inflammatory effects of curcumin in the inflammatory diseases: status, limitations and countermeasures. *Drug Des Devel Ther.* 2021;15:4503–4525. doi: [10.2147/DDDT.S327378](https://doi.org/10.2147/DDDT.S327378)
- [10] Norris L, Karmokar A, Howells L, et al. The role of cancer stem cells in the anti-carcinogenicity of curcumin. *Mol Nutr Food Res.* 2013;57(9):1630–1637. doi: [10.1002/mnfr.201300120](https://doi.org/10.1002/mnfr.201300120)
- [11] Mansouri K, Rasoulpoor S, Daneshkhan A, et al. Clinical effects of curcumin in enhancing cancer therapy: A systematic review. *BMC Cancer.* 2020;20(1):791. doi: [10.1186/s12885-020-07256-8](https://doi.org/10.1186/s12885-020-07256-8)
- [12] Yun DG, Lee DG. Antibacterial activity of curcumin via apoptosis-like response in *Escherichia coli*. *Appl Microbiol Biotechnol.* 2016;100(12):5505–5514. doi: [10.1007/s00253-016-7415-x](https://doi.org/10.1007/s00253-016-7415-x)
- [13] Gunes H, Gulen D, Mutlu R, et al. Antibacterial effects of curcumin: an in vitro minimum inhibitory concentration study. *Toxicol Ind Health.* 2016;32(2):246–250. doi: [10.1177/0748233713498458](https://doi.org/10.1177/0748233713498458)
- [14] Izui S, Sekine S, Maeda K, et al. Antibacterial activity of curcumin against periodontopathic bacteria. *J Periodontol.* 2016;87(1):83–90. doi: [10.1902/jop.2015.150260](https://doi.org/10.1902/jop.2015.150260)
- [15] Izui S, Sekine S, Murai H, et al. Inhibitory effects of curcumin against cytotoxicity of *Porphyromonas gingivalis* outer membrane vesicles. *Arch Oral Biol.* 2021;124:105058. doi: [10.1016/j.archoralbio.2021.105058](https://doi.org/10.1016/j.archoralbio.2021.105058)
- [16] Gottumukkala SN, Koneru S, Mannem S, et al. Effectiveness of sub gingival irrigation of an indigenous 1% curcumin solution on clinical and microbiological parameters in chronic periodontitis patients: a pilot randomized clinical trial. *Contemp Clin Dent.* 2013;4(2):186–191. doi: [10.4103/0976-237X.114874](https://doi.org/10.4103/0976-237X.114874)
- [17] Muglikar S, Patil KC, Shivswami S, et al. Efficacy of curcumin in the treatment of chronic gingivitis: a pilot study. *Oral Health Prev Dent.* 2013;11(1):81–86. doi: [10.3290/j.ohpd.a29379](https://doi.org/10.3290/j.ohpd.a29379)
- [18] Bhatia M, Urolagin SS, Pentyala KB, et al. Novel therapeutic approach for the treatment of periodontitis by curcumin. *J Clin Diagn Res.* 2014;8(12):ZC65–9. doi: [10.7860/JCDR/2014/8231.5343](https://doi.org/10.7860/JCDR/2014/8231.5343)
- [19] Tyagi P, Singh M, Kumari H, et al. Bactericidal activity of curcumin I is associated with damaging of bacterial membrane. *PLOS ONE.* 2015;10(3):e0121313. doi: [10.1371/journal.pone.0121313](https://doi.org/10.1371/journal.pone.0121313)
- [20] Rai D, Singh JK, Roy N, et al. Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity. *Biochem J.* 2008;410(1):147–155. doi: [10.1042/BJ20070891](https://doi.org/10.1042/BJ20070891)
- [21] Shahzad M, Millhouse E, Culshaw S, et al. Combet E. Selected dietary (poly)phenols inhibit periodontal pathogen growth and biofilm formation. *Food Funct.* 2015;6(3):719–729. doi: [10.1039/c4fo01087f](https://doi.org/10.1039/c4fo01087f)
- [22] Hashino E, Kuboniwa M, Alghamdi SA, et al. Erythritol alters microstructure and metabolomic profiles of biofilm composed of streptococcus gordonii and porphyromonas gingivalis. *Mol Oral Microbiol.* 2013;28(6):435–451. doi: [10.1111/omi.12037](https://doi.org/10.1111/omi.12037)
- [23] Amano A, Nakagawa I, Kataoka K, et al. Distribution of *Porphyromonas gingivalis* strains with fimA genotypes in periodontitis patients. *J Clin Microbiol.* 1999;37(5):1426–1430. doi: [10.1128/JCM.37.5.1426-1430.1999](https://doi.org/10.1128/JCM.37.5.1426-1430.1999)
- [24] McClellan DL, Griffen AL, Leys EJ. Age and prevalence of *porphyromonas gingivalis* in children. *J Clin Microbiol.* 1996;34(8):2017–2019. doi: [10.1128/jcm.34.8.2017-2019.1996](https://doi.org/10.1128/jcm.34.8.2017-2019.1996)
- [25] Wösten MM. Eubacterial sigma-factors. *FEMS Microbiol Rev.* 1998;22(3):127–150. doi: [10.1016/S0168-6445\(98\)00011-4](https://doi.org/10.1016/S0168-6445(98)00011-4)
- [26] James CE, Hasegawa Y, Park Y, et al. LuxS involvement in the regulation of genes coding for hemin and iron acquisition systems in *Porphyromonas gingivalis*. *Infect Immun.* 2006;74(7):3834–3844. doi: [10.1128/IAI.01768-05](https://doi.org/10.1128/IAI.01768-05)
- [27] Ohara-Nemoto Y, Rouf SM, Naito M, et al. Identification and characterization of prokaryotic dipeptidyl-peptidase 5 from *Porphyromonas gingivalis*. *J Biol Chem.* 2014;289(9):5436–5448. doi: [10.1074/jbc.M113.527333](https://doi.org/10.1074/jbc.M113.527333)
- [28] Yamasaki T, Nagata A, Kiyoshige T, et al. Black-pigmented, asaccharolytic bacteroides species resembling *porphyromonas gingivalis* (*bacteroides gingivalis*) from beagle dogs. *Oral Microbiol Immunol.* 1990;5(6):332–335. doi: [10.1111/j.1399-302x.1990.tb00436.x](https://doi.org/10.1111/j.1399-302x.1990.tb00436.x)
- [29] Shah HN, Williams RAD. Utilization of glucose and amino acids by *Bacteroides intermedius* and *Bacteroides gingivalis*. *Curr Microbiol.* 1987;15(5):241–246. doi: [10.1007/BF01589374](https://doi.org/10.1007/BF01589374)
- [30] Takahashi N, Sato T, Yamada T. Metabolic pathways for cytotoxic end product formation from glutamate- and aspartate-containing peptides by *porphyromonas gingivalis*. *J Bacteriol.* 2000;182(17):4704–4710. doi: [10.1128/JB.182.17.4704-4710.2000](https://doi.org/10.1128/JB.182.17.4704-4710.2000)
- [31] Mazumdar V, Snitkin ES, Amar S, et al. Metabolic network model of a human oral pathogen. *J Bacteriol.* 2009;191(1):74–90. doi: [10.1128/JB.01123-08](https://doi.org/10.1128/JB.01123-08)
- [32] Yoshida Y, Sasaki T, Ito S, et al. Identification and molecular characterization of tryptophanase encoded by tnaA in *Porphyromonas gingivalis*. *Microbiology (Reading).* 2009;155(Pt 3):968–978. doi: [10.1099/mic.0.024174-0](https://doi.org/10.1099/mic.0.024174-0)
- [33] Kuboniwa M, Houser JR, Hendrickson EL, et al. Metabolic crosstalk regulates *porphyromonas gingivalis* colonization and virulence during oral polymicrobial infection. *Nat Microbiol.* 2017;2(11):1493–1499. doi: [10.1038/s41564-017-0021-6](https://doi.org/10.1038/s41564-017-0021-6)

- [34] Tsu BV, Saier MH, Rokas A. The LysE superfamily of transport proteins involved in cell physiology and pathogenesis. *PLOS ONE*. 2015;10(10):e0137184. doi: [10.1371/journal.pone.0137184](https://doi.org/10.1371/journal.pone.0137184)
- [35] Sindhu RK, Desai HV. Purification and properties of agmatine iminohydrolase from groundnut cotyledons. *Phytochemistry*. 1979;18(12):1937–1938. doi: [10.1016/S0031-9422\(00\)82706-5](https://doi.org/10.1016/S0031-9422(00)82706-5)
- [36] Smith TA. Arginine decarboxylase of oat seedlings. *Phytochemistry*. 1979;18(9):1447–1452. doi: [10.1016/S0031-9422\(00\)98473-5](https://doi.org/10.1016/S0031-9422(00)98473-5)
- [37] Balasundaram D, Tyagi AK. Modulation of arginine decarboxylase activity from mycobacterium smegmatis. *Eur J Biochem*. 1989;183(2):339–345. doi: [10.1111/j.1432-1033.1989.tb14934.x](https://doi.org/10.1111/j.1432-1033.1989.tb14934.x)
- [38] Gevrekci A. The roles of polyamines in microorganisms. *World J Microbiol Biotechnol*. 2017;33(11):204. doi: [10.1007/s11274-017-2370-y](https://doi.org/10.1007/s11274-017-2370-y)
- [39] Sakanaka A, Kuboniwa M, Shimma S, et al. *Fusobacterium nucleatum* metabolically integrates commensals and pathogens in oral biofilms. *mSystems*. 2022;7(4):e0017022. doi: [10.1128/mSystems.00170-22](https://doi.org/10.1128/mSystems.00170-22)
- [40] Kumber VM, Peram MR, Kugaji MS, et al. Effect of curcumin on growth, biofilm formation and virulence factor gene expression of *Porphyromonas gingivalis*. *Odontology*. 2021;109(1):18–28. doi: [10.1007/s10266-020-00514-y](https://doi.org/10.1007/s10266-020-00514-y)
- [41] Nandy P. The role of sigma factor competition in bacterial adaptation under prolonged starvation. *Microbiology (Reading)*. 2022;168(5). doi: [10.1099/mic.0.001195](https://doi.org/10.1099/mic.0.001195)
- [42] Hutcherson JA, Gogeneni H, Yoder-Himes D, et al. Comparison of inherently essential genes of *Porphyromonas gingivalis* identified in two transposon-sequencing libraries. *Mol Oral Microbiol*. 2016;31(4):354–364. doi: [10.1111/omi.12135](https://doi.org/10.1111/omi.12135)
- [43] Jurado P, Fernandez LA, de Lorenzo V. Sigma 54 levels and physiological control of the *Pseudomonas putida* Pu promoter. *J Bacteriol*. 2003;185(11):3379–3383. doi: [10.1128/JB.185.11.3379-3383.2003](https://doi.org/10.1128/JB.185.11.3379-3383.2003)
- [44] Nemoto TK, Ohara NY. Dipeptidyl-peptidases: Key enzymes producing entry forms of extracellular proteins in asaccharolytic periodontopathic bacterium *porphyromonas gingivalis*. *Mol Oral Microbiol*. 2021;36(2):145–156. doi: [10.1111/omi.12317](https://doi.org/10.1111/omi.12317)
- [45] Huang PK, Lin SR, Chang CH, et al. Natural phenolic compounds potentiate hypoglycemia via inhibition of dipeptidyl peptidase IV. *Sci Rep*. 2019;9(1):15585. doi: [10.1038/s41598-019-52088-7](https://doi.org/10.1038/s41598-019-52088-7)
- [46] Gallwitz B. Clinical Use of DPP-4 Inhibitors. *Front Endocrinol*. 2019;10:389. doi: [10.3389/fendo.2019.00389](https://doi.org/10.3389/fendo.2019.00389)
- [47] Gallwitz B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update). *Drugs Today (Barc)*. 2007;43(11):801–814. doi: [10.1358/dot.2007.43.11.1157620](https://doi.org/10.1358/dot.2007.43.11.1157620)
- [48] Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. *Diabetes*. 2005;54(10):2988–2994. doi: [10.2337/diabetes.54.10.2988](https://doi.org/10.2337/diabetes.54.10.2988)
- [49] Rea D, Van Elzen R, De Winter H, et al. Crystal structure of *Porphyromonas gingivalis* dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling. *Eur J Med Chem*. 2017;139:482–491. doi: [10.1016/j.ejmech.2017.08.024](https://doi.org/10.1016/j.ejmech.2017.08.024)
- [50] Takahashi N. Oral microbiome metabolism: from “who are they?” to “what are they doing?”. *J Dent Res*. 2015;94(12):1628–1637. doi: [10.1177/0022034515606045](https://doi.org/10.1177/0022034515606045)
- [51] Zheng D, Huang C, Huang H, et al. Antibacterial mechanism of curcumin: a review. *Chem Biodivers*. 2020;17(8):e2000171. doi: [10.1002/cbdv.202000171](https://doi.org/10.1002/cbdv.202000171)
- [52] Hussain Y, Alam W, Ullah H, et al. Antimicrobial Potential of Curcumin: therapeutic potential and challenges to clinical applications. *Antibiotics (Basel)*. 2022;11(3):322. doi: [10.3390/antibiotics11030322](https://doi.org/10.3390/antibiotics11030322)